EUVIMEDEUVIMED entdecken
Crossref

Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis

Qin-Xiao Wang, Hai-Yang He, Ying-Luo Niu, Sheng Fang iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Qin-Xiao Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Protein Kinase Inhibitors, Amyloidosis, Familial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic. Disease severity was assessed using body surface area (BSA), Peak Pruritus Numerical Rating Scale (PP‐NRS), and Investigator Global Assessment (IGA) scores. Significant improvements were observed in BSA ( p < 0.05), PP‐NRS ( p < 0.001), and IGA ( p < 0.01) at week 4. Treatment was well tolerated, with no serious adverse events leading to discontinuation. The findings of this study suggest that tofacitinib could be an appealing approach for treating PLCA. Further large‐scale, randomized controlled trials are necessary to confirm its long‐term efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesPiperidinesProtein Kinase InhibitorsAmyloidosis, FamilialSkin Diseases, GeneticPyrrolesHumansMaleFemaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedPruritusSeverity of Illness IndexAdultBody Surface AreaSkin

Stichwörter der Autor:innen

PLCAefficacypruritustofacitinibtreatment

Substanzen

tofacitinibPyrimidinesPiperidinesProtein Kinase InhibitorsPyrroles

Autor:innen und Institutionen

  • Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Sheng Fang

Zitieren

APA

Wang, Q. X., He, H. Y., Niu, Y. L., & Fang, S. (2025). Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17869

Vancouver

Wang QX, He HY, Niu YL, Fang S. Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17869

BibTeX
@article{Wang2025,
  author = {Wang, Qin-Xiao and He, Hai-Yang and Niu, Ying-Luo and Fang, Sheng},
  title = {Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17869}
}
Kostenlos starten →